Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab +/- Atezolizumab in R/R B-cell NHL and CLL
NCT02500407Phase 2Completed
- Sponsor
- Genentech
- Start
- Sep 2015
- Primary completion
- May 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of mosunetuzumab in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), sponsored by Genentech. Started Sep 2015; status: completed.
02
Drugs
mosunetuzumab
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02500407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500407.